NCT07072195View on ClinicalTrials.gov

A Study of AMC6156 in People With Sarcopenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions
Sarcopenia in ElderlySarcopenia
Interventions
DRUG

AMC6156 0.1mg

Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.

DRUG

AMC6156 0.3mg

Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.

DRUG

AMC6156 1.0mg

Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.

DRUG

Placebo

Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.

Trial Locations (4)

13496

RECRUITING

CHA Bundang Medical Center, Seongnam-si

13620

NOT_YET_RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

16499

RECRUITING

Ajou University Hospital, Suwon

03080

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Animuscure Inc.

INDUSTRY